445 related articles for article (PubMed ID: 9415071)
21. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
[TBL] [Abstract][Full Text] [Related]
22. The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms.
Lotfy M; Singh J; Rashed H; Tariq S; Zilahi E; Adeghate E
Cell Tissue Res; 2014 Nov; 358(2):343-58. PubMed ID: 25115772
[TBL] [Abstract][Full Text] [Related]
23. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7-37)/polymer conjugate to isolated rat islets.
Kim S; Wan Kim S; Bae YH
Biomaterials; 2005 Jun; 26(17):3597-606. PubMed ID: 15621250
[TBL] [Abstract][Full Text] [Related]
26. Excessive islet NO generation in type 2 diabetic GK rats coincides with abnormal hormone secretion and is counteracted by GLP-1.
Salehi A; Meidute Abaraviciene S; Jimenez-Feltstrom J; Ostenson CG; Efendic S; Lundquist I
PLoS One; 2008 May; 3(5):e2165. PubMed ID: 18478125
[TBL] [Abstract][Full Text] [Related]
27. Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.
Gromada J; Ding WG; Barg S; Renström E; Rorsman P
Pflugers Arch; 1997 Sep; 434(5):515-24. PubMed ID: 9242714
[TBL] [Abstract][Full Text] [Related]
28. Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone.
Matsuyama T; Komatsu R; Namba M; Watanabe N; Itoh H; Tarui S
Diabetes Res Clin Pract; 1988 Oct; 5(4):281-4. PubMed ID: 3069410
[TBL] [Abstract][Full Text] [Related]
29. GLP-1(7-36) amide stimulates insulin secretion in rat islets: studies on the mode of action.
Fridolf T; Ahrén B
Diabetes Res; 1991 Apr; 16(4):185-91. PubMed ID: 1802486
[TBL] [Abstract][Full Text] [Related]
30. Glucagonlike peptide I (7-37) actions on endocrine pancreas.
Weir GC; Mojsov S; Hendrick GK; Habener JF
Diabetes; 1989 Mar; 38(3):338-42. PubMed ID: 2645190
[TBL] [Abstract][Full Text] [Related]
31. Biophysical and pharmacological properties of glucagon-like peptide-1 in rats under isoflurane anesthesia.
Kawano T; Tanaka K; Chi H; Eguchi S; Yamazaki F; Kitamura S; Kumagai N; Yokoyama M
Anesth Analg; 2012 Jul; 115(1):62-9. PubMed ID: 22504208
[TBL] [Abstract][Full Text] [Related]
32. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide.
Heller RS; Aponte GW
Am J Physiol; 1995 Dec; 269(6 Pt 1):G852-60. PubMed ID: 8572216
[TBL] [Abstract][Full Text] [Related]
33. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene.
Flamez D; Van Breusegem A; Scrocchi LA; Quartier E; Pipeleers D; Drucker DJ; Schuit F
Diabetes; 1998 Apr; 47(4):646-52. PubMed ID: 9568699
[TBL] [Abstract][Full Text] [Related]
34. Evidence that glucagon stimulates insulin secretion through its own receptor in rats.
Kawai K; Yokota C; Ohashi S; Watanabe Y; Yamashita K
Diabetologia; 1995 Mar; 38(3):274-6. PubMed ID: 7758872
[TBL] [Abstract][Full Text] [Related]
35. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.
Suzuki S; Kawai K; Ohashi S; Mukai H; Murayama Y; Yamashita K
Diabetes; 1990 Nov; 39(11):1320-5. PubMed ID: 2146178
[TBL] [Abstract][Full Text] [Related]
36. Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1.
Siegel EG; Seidenstücker A; Gallwitz B; Schmitz F; Reinecke-Lüthge A; Klöppel G; Fölsch UR; Schmidt WE
J Endocrinol; 2000 Jan; 164(1):13-9. PubMed ID: 10607933
[TBL] [Abstract][Full Text] [Related]
37. Glucagon-like peptide-1 stimulates insulin secretion but not phosphoinositide hydrolysis from islets desensitized by prior exposure to high glucose or the muscarinic agonist carbachol.
Zawalich WS; Zawalich KC
Metabolism; 1996 Feb; 45(2):273-8. PubMed ID: 8596502
[TBL] [Abstract][Full Text] [Related]
38. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
39. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
40. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets.
Fehmann HC; Hering BJ; Wolf MJ; Brandhorst H; Brandhorst D; Bretzel RG; Federlin K; Göke B
Pancreas; 1995 Aug; 11(2):196-200. PubMed ID: 7479679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
